Insmed is a healthcare company focused on developing and commercializing innovative therapies for patients with serious and rare diseases. Its core products include treatments for pulmonary diseases, particularly those related to cystic fibrosis and other chronic conditions. The company primarily generates revenue through the sale of its pharmaceutical products, with a strong emphasis on research and development to expand its product pipeline.
The investment profile of Insmed is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue increases. However, the high risk associated with its current financial performance and volatility may deter conservative investors. The stock may appeal to those with a medium to long-term investment horizon, seeking exposure to innovative healthcare solutions.
| Datum | Vorher | Nachher | Grund |
|---|---|---|---|
| 2026-05-08 15:23 | — | Verkaufen | scenario_deterioration |
| 2026-05-08 05:37 | Halten | Verkaufen | scenario_deterioration |
| 2026-04-02 07:41 | Verkaufen | Halten | Компания показывает сильный рост выручки и положительную динамику в краткосрочной перспективе, однако отрицательный EPS и высокая волатильность указывают на риски. |
| Datum | Analyst | Action | Ziel | Preis damals |
|---|---|---|---|---|
| 2026-05-13 17:11 | Truist Financial | Ziel gesenkt | 205 → 185 | 116.555 |
| 2026-05-08 11:49 | Wells Fargo | Ziel gesenkt | 177 → 160 | 105 |
| 2026-05-08 11:11 | Guggenheim | Ziel gesenkt | 230 → 226 | 105 |
